Research Analysts Offer Predictions for CRBP Q2 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Investment analysts at William Blair issued their Q2 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a report issued on Tuesday, May 6th. William Blair analyst A. Hsieh expects that the biopharmaceutical company will earn ($0.89) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. William Blair also issued estimates for Corbus Pharmaceuticals’ Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($4.28) EPS, Q1 2026 earnings at ($1.02) EPS, Q2 2026 earnings at ($1.01) EPS, Q3 2026 earnings at ($1.08) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.19) EPS and FY2027 earnings at ($5.58) EPS.

Several other equities research analysts have also issued reports on the company. Royal Bank of Canada reduced their price target on Corbus Pharmaceuticals from $65.00 to $58.00 and set an “outperform” rating for the company in a report on Wednesday. StockNews.com raised shares of Corbus Pharmaceuticals to a “sell” rating in a research report on Thursday, March 6th. HC Wainwright cut their price target on shares of Corbus Pharmaceuticals from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Wednesday. Oppenheimer decreased their price objective on shares of Corbus Pharmaceuticals from $60.00 to $56.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Jefferies Financial Group cut their target price on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

Corbus Pharmaceuticals Trading Down 3.0 %

CRBP opened at $6.45 on Friday. The stock has a fifty day moving average price of $6.33 and a 200 day moving average price of $10.81. Corbus Pharmaceuticals has a 1 year low of $4.64 and a 1 year high of $61.90. The stock has a market cap of $78.90 million, a price-to-earnings ratio of -1.38 and a beta of 3.19.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.13).

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN grew its stake in shares of Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 2,195 shares during the last quarter. Avanza Fonder AB bought a new stake in shares of Corbus Pharmaceuticals in the fourth quarter valued at about $84,000. Deutsche Bank AG grew its position in Corbus Pharmaceuticals by 46.8% during the fourth quarter. Deutsche Bank AG now owns 8,206 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 2,616 shares in the last quarter. Aquatic Capital Management LLC bought a new position in Corbus Pharmaceuticals during the fourth quarter valued at about $101,000. Finally, JPMorgan Chase & Co. raised its holdings in Corbus Pharmaceuticals by 27.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 1,172 shares in the last quarter. 64.64% of the stock is owned by institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.